L9 - Transplantation Flashcards

1
Q

what are the types of transplantation?

A

1)Autograft
–Graft originates from the patient him/herself
–Split-skin graft or full-thickness skin graft for skin transplantation
–Saphenous vein graft for vascular bypass surgery
Bone graft from the iliac crest for bone reconstruction
2)Isograft
Graft originates from a genetically identical person (identical twin)
Various organ transplantations (e.g., kidney, liver, or cornea)
3)Allograft
–Graft originates from a genetically different person
4)Xenograft
–Graft originates from different species (e.g., pig)
–Porcine or bovine heart valves

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

examples of tissue transplantation…

A

Non-vascularized, non-hematopoietic tissue
Immunologically inert
• Bone grafts
• Heart valves
• Corneas (occasionally need immunosuppression)
• Blood vessels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is the HSCT?

A

The transplantation of hematopoietic stem cells, which arise from peripheral blood, bone marrow transplant, or umbilical cord blood. There are two types of stem cell transplantation: autologous (removal of the patient’s own hematopoietic stem cells) and allogenous (transfer of hematopoietic stem cells from a sibling or donor).
–Also cord blood stem cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are the indications of autologous HSCT?

A
  • -To allow the administration of higher doses of antineoplastic therapy than would otherwise be possible for certain non-hematological malignancies (e.g., germ cell tumors, soft tissue sarcoma)
  • -Multiple myeloma
  • -Lymphoma
  • -High-dose chemotherapy would destroy the bone marrow and therefore cannot be used to treat neoplastic disease without subsequent bone marrow transplantation.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what are the indications of allogenous HSCT?

A
  • -To replace abnormal but non-malignant cells of the lymphohematopoietic system with hematopoietic cells from a normal donor
  • -Severe combined immunodeficiency
  • -Aplastic anemia
  • -Thalassemia
  • -Leukemia (e.g., acute lymphoblastic leukemia)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what solid organs can be transplanted?

A
  • Kidney
  • Pancreas
  • Liver
  • Heart
  • Lung
  • Islet cell transplantation
  • Small bowel
  • Vascularized composite grafts
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what are the indications of solid organ transplantation?

A
  • Irreversible organ failure
  • Disease with low risk of recurrence
  • Recipient free of infection
  • Recipient free of malignancy
  • Recipient fit for major surgery
  • Recipient psychologically suitable
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what are the CI’s for organ donation?

A
  • -Malignancy that is non-curable or metastatic
  • -Sepsis in the donor
  • -Transmissible spongiform encephalopathies (prion diseases such as Creutzfeldt-Jakob disease)
  • -Cardiac arrest occurring before brain death (This comprises patients who suffer a sudden, unexpected cardiac arrest; the subsequent decline in bloodflow is associated with a high risk for thrombosis and ischemia of organs. This category should not be confused with deceased donors after cardiac death (DCD), who receive heparin before circulation ceases to prevent thrombosis.)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

does
–Low-grade, localized tumors without evidence of metastasis at the time of death
–History of malignancy with a disease-free duration > 5 years
–Hepatitis B or C infection
–HIV infection
–Hypertension, diabetes, and/or elderly patients
are CIs for organ donation?

A

no
HIV infection was previously an absolute contraindication for organ donation and legally prohibited individuals from becoming organ donors in the US, but the HIV Organ Policy Equity (HOPE) Act implemented in November 2015 allows the transplantation of organs from HIV-positive donors into HIV-positive recipients at certain institutions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are the ethical issues in organ transplantation?

A
  • Allocation of scarce resources

* Living donor programme

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is the allorecognition?

A
  • -Definition: recognition of a foreign antigen as a non-self antigen by a host
  • -Clinical importance: Activation of a particular T-cell by a foreign HLA peptide results in clonal proliferation of that type of T lymphocyte, a process that is mediated by IL-2 → acute rejection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is the HLA matching?

A

• Relevant to solid organ and HSCT
• Better matching decreases the immunological barrier
• Better outcomes
• Less sensitisation (anti-HLA antibodies)
–MHC matching at the HLA-DR, HLA-A, and HLA-B loci
–The major histocompatibility complex (MHC) of both donor and recipient should correspond as much as possible in order to minimize the risk of transplant rejection. The matching of HLA-C, HLA-DP, and HLA-DQ is preferred but is not always required.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

important concepts of transplant immunology

A

–MHC: a gene cluster on chromosome 6 that codes for human leukocyte antigen (HLA) molecules.
–HLA: proteins present on the surface of all cells that display antigenic peptides as a normal physiological function so that they can be recognized by T-lymphocytes as either self or non-self antigens.
Types of MHC
–MHC I cluster, which codes for class I HLA molecules, consists of three loci: HLA-A, HLA-B, and HLA-C.
–MHC II cluster, which codes for class II HLA molecules, also consists of three loci: HLA-DR, HLA-DP, and HLA-DQ.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

classification of graft rejection?

A
  • Hyperacute: <24 hours
  • Acute cellular: common <6 mths
  • Acute antibody-mediated: usually < 6 weeks
  • Chronic rejection:
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is the mechanism of tissue damage in graft rejection?

A
•	Hyper-acute &amp;acute antibody-mediated 
Antibody &amp; complement
Acute inflammation &amp; thrombosis
•	Cellular Rejection
T cell cytotoxic damage
•	Chronic Rejection
Role of antibodies now prominent 
Scarring in response to injury
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is the pathophysiology of hyperacute graft rejection?

A
  • -Preformed cytotoxic antibodies against class I HLA molecules or blood group antigens are present → activation of complement system and adhesion to granulocytes → thrombosis of vessels → graft ischemia
  • -Preformed antibodies against HLA antigens occur as result of a exposure to foreign HLA haplotypes during pregnancy, transfusion, or a previously failed transplantation. Preformed antibodies against blood group antigens are usually the result of ABO incompatibility.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what is the pathophysiology of acute graft rejection?

A
  • -Allorecognition → T-lymphocyte induced cell-mediated and/or humoral immunity
  • -Donor MHC class II antigens react with host CD4+ T cells → differentiate into Th1 helper T cells → cytokine (INF-γ) release → macrophage recruitment → parenchymal and endothelial inflammation (type IV hypersensitivity reaction)
  • -Donor MHC class I antigens react with host CD8+ T cells → direct cytotoxic cell damage (typ
18
Q

what is the pathophysiology of chronic graft rejection?

A

1)Irreversible interstitial fibrosis and obstruction of vessels
2)The underlying mechanism is not entirely understood but involves a host CD4+ T cell response against donor antigens in a type IV hypersensitivty reaction
3)Risk factors
–Previous episode of acute rejection
–Poor HLA match
–Prolonged cold ischemia time
–Hyperlipidemia
Inadequate immunosuppression or non-compliance

19
Q

preformed antibodies to graft cause what type of rejection?

A
  • Can cause hyper-acute rejection
  • Contraindication (except for liver transplants)
  • Blood group antibodies (ABO & other)
  • Anti-HLA antibodies
20
Q

what aspects of clinical history suggest possible sensitization?

A
  • Transfusion
  • Pregnancy
  • Previous allograft
21
Q

in what situations non-classical sensitization occurs?

A

–Rare causes – dural patches, heart valves
–Environmental exposures
–Infection
• HIV, EBV & others
Artificial surfaces
–LVADs (Left ventricular assist devices)
–AIDs ( Artificial implantable defibrillators)

22
Q

what is the statistical outcome of organ transplantation?

A

Kidney Liver
Heart Lung
1 yr graft survival: >95% >90%
>90% >90%
3 yrs graft survival: 87% 80%
80% 65%

23
Q

how haemopoietic stem cells are mobilized for transplantation?

A

with growth factors

24
Q

what are the indications for HSCT?

A
•	Malignant disease
--Leukaemia &amp; lymphoma
--Solid organ tumours, multiple myeloma
•	Genetic diseases
--Immunodeficiency &amp;haematological storage disorders
•	Autoimmune disease (rare; few units)
25
Q

how HSC are trnapsplanted?

A
  • Bone marrow/stem cells collected and processed
  • Often depleted of mature T cells
  • Patient’s bone marrow ablated “Conditioning”
  • Infusion given
  • Patient isolated until white cells recover
26
Q

what are the complications of HSCT?

A
  • Non-engraftment
  • Infection
  • GvHD
  • Recurrence
  • Toxicity of conditioning regimen
27
Q

what is the GVHD?

A

A transplantation-associated immunologic reaction that occurs when immunocompetent donor T lymphocytes in the graft recognize the recipient (host) as foreign, resulting in a systemic inflammatory reaction. Typically affects the skin (rash), gastrointestinal tract (nausea, diarrhea), and the liver (elevated liver enzymes). Primarily occurs in allogenous hematopoietic stem-cell transplantation recipients.

28
Q

GVHD occurs only in HSCT. True/False

A

False

  • -Allogenous hematopoietic stem-cell transplantation
  • -Small bowel transplantation (small bowel contains lymphoid tissue, which increases the risk of graft-versus-host disease.)
  • -Transfusion of non-irradiated blood products
29
Q

what are the signs and symptoms of acute GVHD?

A
  • pruritic or painful maculopapular rash
  • -Nausea, vomiting, diarrhea, and/or cramping abdominal pain
  • -Hepatic dysfunction: jaundice
30
Q

what are the signs and symptoms of chronic GVHD?

A
  • -Scleroderma-like and lichenoid skin changes
  • -Sicca syndrome: xerophthalmia, xerostomia, dry pruritic skin
  • -Chronic enteritis (similar to inflammatory bowel disease): bloody diarrhea, abdominal pain, weight loss
  • -Hepatic dysfunction: jaundice
  • -Bronchiolitis obliterans: chronic cough, wheezing, and dyspnea that is not responsive to bronchodilator therapy
  • -Myasthenic symptoms, polymyositis: weakness, muscle pain
31
Q

what are the prerequisites for organ matching

A

1_Cross-matching

  • -Recipient serum is examined for preformed antibodies against donor T and B lymphocytes.
    2) ABO compatibility
  • -Hematopoietic stem cell transplantation: ABO compatibility is preferred but incompatibility can be tolerated.
  • -Solid organ transplantation: ABO compatibility is required.
    3) Histocompatibility
  • -MHC matching at the HLA-DR, HLA-A, and HLA-B loci
32
Q

does Rh compatibility required for solid organ transplantation?

A

Rh compatibility is not required for solid organ transplantation. Both Rh compatibility and ABO compatibility are not essential for hematopoietic stem cell transplantation!

33
Q

what organs are transplanted from living donors?

A

Only kidney transplantation and liver transplantation can be performed using grafts from living donors.

34
Q

what is the post-transplant immunosuppressive therapy?

A

1) Induction therapy using anti-T-lymphocyte antibodies
- -Lymphocyte-depleting antibodies (polyclonal): thymoglobulin
- -Non-depleting antibodies (monoclonal): basiliximab
- -Maintenance therapy: commonly via a triple-drug regimen
2) Corticosteroids
- -Calcineurin inhibitor (e.g., cyclosporine, or tacrolimus)
- -Antiproliferative agents (e.g., azathioprine, mycophenolate mofetil, or sirolimus)

35
Q

what is the basiliximab?

A

monoclonal antibody that blocks the IL-2 receptor. Used as part of an immunosuppressive regimen, particularly for patients who have undergone kidney transplantation. Adverse effects include edema, hypertension, and tremor.

36
Q

what is the difference between cyclosporine vs tacrolimus?

A

1)cyclosporine binds cyclophilin → inhibition of calcineurin → inhibition of NFAT activation→ ↓ IL-2 transcription → ↓ activation of T cells
Cytostatic action: binding to multidrug resistance glycoprotein P-170
2)tacrolimus Binding to FK506 binding protein (FKBP) → inhibition of calcineurin → inhibition of NFAT activation → ↓ IL-2 transcription → ↓ activation of T cells
3)Many side effects of tacrolimus are similar to cyclosporine A, but tacrolimus does not cause gingival hyperplasia or hypertrichosis!

37
Q

what is the role of calcineurin?

A

Physiologically, calcineurin activates the nuclear factor of activated T cell (NFAT) by dephosphorylating its serine-threonine residues. Activated NFAT binds to DNA and enables transcription of a number of cytokines (most prominently, IL-2) and other molecules (e.g., VEGF).Transcription of IL-2 ultimately leads to activation of Th2, CD8 and NK cells.

38
Q

what are the early-onset post-transplant infections? <1 month

A
  • -surgical site infections
  • -Other hospital-acquired infections (e.g., nosocomial urinary tract infection)
  • -Candidiasis
  • -C. difficile
39
Q

what are the early-onset post-transplant infections? 1-6 months

A

1–6 months
HHV-6, HHV-7
HSV

40
Q

what are the early-onset post-transplant infections? 6-12 months

A

1) Viral infections
- -CMV
- -HSV
- -VZV
- -EBV
- -Adenovirus
- -BK polyomavirus
- -Hepatitis B, hepatitis C viruses
2) Pneumocystis carinii pneumonia
3) Listeriosis
4) Nocardiosis

41
Q

what are the early-onset post-transplant infections? >12 months

A

1) Viral infections
- -CMV
- -HSV
- -VZV
- -EBV → post-transplant lymphoproliferative disease
- -JC polyomavirus
- -HPV
2) Tuberculosis
3) Invasive fungal infections
- -Aspergillosis
- -Coccidioidomycosis
- -Histoplasmosis
- -Cryptococcal meningitis